glucose 6-phosphate (in HbA 1a2 ) (9, 10 ) . Furthermore, Hb can be glycated at multiple sites, including the amino terminus, as well as certain ⑀-amino groups (9 ) . There is no accurate information about the globin chains of HbA 1d1 , HbA 1d2 , and HbA 1e available in the literature. Possibly, HbA 1d1 contains a globin chain modified by acetaldehyde (11 ) . On the other hand, the well-studied HbA 1d3 is composed of at least 2 components, HbA 1d3a and HbA 1d3b , containing a carbamylated (urea adduct) ␣-chain and a glycated minor Hb (4 ) . Additionally, a novel Hb-glutathione adduct, which is increased in patients with diabetes and elutes in the HbA 1d3 fraction, has been reported (12, 13 ) .
Acetylation and Hb adducts of aspirin, vitamin C, penicillin, and acetyl-CoA are additional posttranslational modifications (14 ) . Additionally, Hb adducts with pyruvic acid at the amino terminus of the ␤-chain (in HbA 1b ) (15 ) or glycoinositolphospholipid at the carboxy terminus of the ␤-chain (16 ) are known.
The exact quantification of minor Hbs has important diagnostic implications. For example, HbA 1c is a marker for diabetes mellitus (1, 17 ) ; HbA 1d3a and HbA 1d3b are increased in uremic and diabetic patients, respectively (4 ) ; and the controversial influence of Hb-acetaldehyde adducts on HbA 1d3 in female heavy drinkers has been reported (4, 11 ) . HbF is increased in hereditary persistence of fetal Hb, ␤-thalassemia intermedia, ␤-thalassemia major, and specific drug treatments (18 ) . Increased HbF is known to inhibit the polymerization of HbS, and the monitoring of HbF concentrations during the follow-up and treatment of patients with sickle cell anemia is mandatory. HbA 2 is increased in ␤-thalassemia and in megaloblastic anemia (1 ) but is decreased in ␣-thalassemia, iron deficiency, and sideroblastic anemia (1, 18 ) .
Quantification of minor Hbs requires precise and specific methods. A widely applied technique is cationexchange HPLC, which, however, is known to give falsely increased HbA 2 values in HbS carriers (5, 19 -21 Suh et al. (19 ) suggested that coelution of HbS adducts, including glycated HbS, with HbA 2 also contributes to increased measured HbA 2 concentrations. Other common Hb analysis techniques include isoelectric focusing, reversed-phase HPLC, and capillary zone electrophoresis (7, 14 ) .
Since the development of soft ionization techniques, electrospray ionization and MALDI-TOF MS have provided precise, rapid, and reliable analysis of Hb components. These techniques are well suited to detect globin chain mutations and posttranslational modifications. To date, however, MALDI-TOF MS has seen remarkably little application to Hb analysis (24, 25 ) despite its advantages, such as high sensitivity and short analysis times. Because many of the ␤-chain variants, including HbC, D-Los Angeles, E, and O-Arab, exhibit mass shifts of only 1 Da, their analyses require high-resolution instruments.
In this study, we used MALDI-TOF MS to investigate globin chains constituting different minor Hbs. We also used this technique to elucidate the minor components in erythrocyte lysates responsible for falsely increased HbA 2 values in HbS patients.
Materials and Methods blood samples
We analyzed a collection of anonymized human blood specimens from a routine chromatography laboratory; therefore, no ethics approval was required. Blood samples had been collected with EDTA or heparin as anticoagulant, stored at 4°C, and generally analyzed within 24 h. For the determination of HbA 2 values, we used fresh samples (Hb analysis with PolyCAT A HPLC is a routine analysis of our hospital). In most cases, analysis was performed within 24 h. For the isolation of different Hb fractions, we used some fresh and some previously collected samples (especially the blood samples from patients with rare diseases). HbA 2 fractions were isolated from fresh samples (in most cases not older than 24 h). We prepared hemolysates for chromatographic analysis by lysing washed erythrocytes in 1 mmol/L KCN. 
sample concentration
We concentrated the isolated Hb fractions to a final volume of 50 L with 5-kDa-cutoff Amicon ® Ultra-4 Centrifugal Filter Devices (Millipore). Before mass spectrometric analysis, we further desalted 10 L of isolated minor Hb samples with C18 ZipTips ® (Millipore) and eluted them with 3 L of 750 mL/L CH 3 CN in 1 mL/L trifluoroacetic acid (TFA). We used 0.5 L of the desalted sample for MALDI-TOF MS.
maldi-tof ms
To analyze globin chains, we used the autoflex system (Bruker Daltonics) for MALDI-TOF MS. The mass reso-lution at 15 kDa was ϳ750 (m/⌬m). Isolated HPLC fractions were analyzed by the overlayer method. We applied a thin layer of sinapinic acid (saturated solution in ethanol) to a ground-steel MALDI target. We then mixed equal volumes of protein sample and a saturated sinapinic acid solution (in 330 mL/L CH 3 CN-1 mL/L TFA), applied 0.5 L of the mixture to the thin layer, and dried the target at room temperature. To analyze the globin digests, we applied 0.5 L of the sample directly to a 600-m AnchorChip TM (Bruker Daltonics) target and added, on top of the analyte solution, 1.1 L of a saturated matrix solution consisting of ␣-cyano-4-hydroxycinnamic acid (in 330 mL/L CH 3 CN-1 mL/L TFA), diluted 1:10 in ethanol-acetone (67:33 by volume). After drying the target at room temperature, we performed on-target washing with 2 L of 1 mL/L TFA.
protein digests Globin chains were digested by adding 1 g of endoproteinase Glu-C (Boehringer Mannheim) or 0.2 g of trypsin (Promega) and 20 L of digestion buffer (25 mmol/L NH 4 HCO 3 , pH 7.8) to the lyophilized sample. The solution was incubated overnight at room temperature (Glu-C digestion) or at 37°C (trypsin digestion).
Results

PolyCAT A HPLC analysis of lysates
A typical PolyCAT A chromatogram of the erythrocyte hemolysate prepared from blood of a healthy donor is shown in Fig. 1A . In addition to the major HbA, a series of minor Hbs are evident, of which the most intense are HbA 1c ; HbA 1d3 with its 2 components, HbA 1d3a and HbA 1d3b ; and HbA 2 . Other Hbs, such as HbA 1a ϩ b , HbA 1d1 ϩ 2 , and HbA 1e , have lower intensities and are only partly resolved. Shown in Fig. 1B is a PolyCAT A chromatogram of the lysate from an individual heterozygous for HbS. Typically, an intense peak corresponding to HbS elutes at a retention time of 30 min. MALDI-TOF analysis of the isolated fraction of HbS revealed 2 globin chains, the ␣-chain at 15 127 Da and the ␤ S -chain at 15 838 Da (Fig. 1B, inset) , whereas the typical ␣-and ␤-chains were detected in the HbA fraction (data not shown).
analysis of minor Hbs by MALDI-TOF MS
A selection of MALDI-TOF mass spectra of isolated fractions containing separated minor Hbs is shown in Fig.  2 . The peaks are assigned according to the expected molecular masses of the globin chains. Table 1 summarizes the globin chains detected in the different fractions. As shown in Fig. 2A , the mass spectrum of a HbA 1b fraction isolated from a patient with glycogenose type I includes peaks that correspond to the ␣-chain (15 127 Da), the pyruvic acid adduct of the ␤-chain (15 938 Da), and the latter's decarboxylated form (15 894 Da). The mass spectra in panels B and C of Fig. 2 correspond to the globin chains in the pre-HbA 1c and the HbA 1c fractions, with glycated ␣-and ␤-chains at molecular masses of 15 289 (Fig. 2B ) and 16 030 Da (Fig. 2, B and C) , respectively. Analysis of the HbC 1 fraction isolated from a patient with HbC revealed a very similar mass spectrum for HbA 1c (data not shown). HbC 1 , a minor Hb eluting slightly before HbC, contains the characteristic ␣-chain and a glycated ␤ C -chain that differs by only 1 Da from the typical glycated ␤-chain, ␤ glyc . Shown in Fig. 2D are the globin chains that produce the HbF 1 peak, a minor Hb in samples with high HbF content. The chains at 15 996 and 16 038 Da are assigned to the G ␥-and the acetylated G ␥-chains, respectively, and both peaks contain a shoulder representing the A ␥-and acetylated A ␥-chains, respectively. Finally, the mass spectra of the partly separated HbA 1d3a (Fig. 2E ) and HbA 1d3b (Fig. 2F ) peaks exhibit several different globin chains at 15 127 (␣-chain), 15 868 (␤-chain), 15 170, and 15 894 Da. From data reported in the literature, we concluded that the peak at 15 170 Da corresponds to the carbamylated ␣-chain (urea adduct), whereas the peak at 15 894 Da is consistent with an acetaldehyde adduct of the ␤-chain. To confirm these assumptions, we digested the globin chains in the fractions with endoproteinase Glu-C or trypsin. After subsequent MALDI-TOF MS analyses of the peptides, we detected the urea adduct with the N-terminal peptide of the ␣-chain (data not shown). The tryptic digest of the peak at 15 894 Da, however, contained no acetaldehyde adduct with the N-terminal peptide of the ␤-chain. We conclude that a site other than the amino terminus must therefore form an adduct with acetaldehyde.
HbA 2 values determined with PolyCAT A HPLC To investigate the reasons for increased HbA 2 concentrations in erythrocyte lysates of HbS carriers, we analyzed 32 samples from different heterozygous HbS patients, 42 samples from homozygous HbS patients, and 200 samples from unaffected controls by cation-exchange HPLC (Poly-CAT A). We also analyzed a second control group that included 47 samples from patients with ␤-thalassemia minor (Table 2) . Compared with the control samples, the HbA 2 concentrations in HbS patients (homozygous and heterozygous) were statistically significantly increased (P Ͻ0.0001, Student t-test). In homozygous and heterozygous HbS patients, the concentrations were 4.95% and 4.22% of total Hb, respectively. These concentrations are clearly increased relative to the concentration (2.68%) measured in the control samples. The HbA 2 concentration in homozygous HbS patients (4.95%) approached that of ␤-thalassemia patients (5.35%).
elucidation of unknown minor Hb
We assumed that a minor Hb coeluted with HbA 2 and thus falsely increased HbA 2 values in patients with sickle cell anemia. We therefore isolated the HbA 2 fractions of 12 HbS samples (3 heterozygotes and 9 homozygotes) and 2 ␤-thalassemia samples. The MALDI-TOF mass spectra of the HbA 2 fractions with 2 intensive peaks at 15 127 and 15 925 Da correspond to the normal ␣-and ␦-chains, respectively (Fig. 3) . Both ␤-thalassemia samples gave similar spectra. On the other hand, the MALDI-TOF mass spectrum of the HbA 2 fraction isolated from a patient with HbS included 4 different globin chains with masses at 15 127, 15 170, 15 838, and 15 925 Da (Fig. 3B ). All HbA 2 fractions isolated from 9 HbS samples gave similar MALDI-TOF mass spectra (data not shown). To exclude artifacts, we purified an isolated HbA 2 fraction of a heterozygous HbS carrier 3 times by cation-exchange chromatography, and MALDI-TOF analysis revealed the peak at 15 838 Da. As in Fig. 3A , the peaks at 15 127 and 15 925 Da were assigned to the normal ␣-and ␦-chains. The peak at 15 838 Da, moreover, corresponds to the ␤ S -chain, whereas the peak at 15 170 Da is consistent with a posttranslationally modified ␣-chain. Considering the results obtained for the HbA 1d3a fraction, we assumed that carbamylation of the ␣-chain accounted for the mass shift of 43 Da compared with the normal ␣-chain. With digestion of the HbA 2 fraction by endoproteinase Glu-C and subsequent MALDI-TOF MS analysis of the resulting peptides, we confirmed this assumption (data not shown). The 15 170-Da globin chain corresponds to the N-terminal-carbamylated ␣-chain.
Discussion
Traditional methods for Hb analysis, such as chromatography and electrophoresis, reveal only symmetric Hb tetramers because of the rapid dissociation of tetramers to dimers relative to the separation time (27 ) . We confirmed this finding by analyzing a heterozygous HbS sample (Fig. 1B) . MALDI-TOF analysis of the isolated HbA and HbS fractions revealed only globin chains of symmetric Hbs, ␣␤ (tetrameric structure, ␣ 2 ␤ 2 ) and ␣␤ S (␣ 2 ␤ 2 S ), re- spectively. We observed no peak for the expected asymmetric tetramer ␣ 2 ␤␤ S , leading us to conclude that the observed peaks in cation-exchange HPLC all correspond to dimers and not to tetramers. The signals in a PolyCAT A chromatogram therefore do not reflect the real tetrameric Hbs.
Use of MALDI-TOF MS to analyze desalted and concentrated minor Hb fractions allows measurement of the globin chains that build the tetrameric structure of the Hb. We applied our procedure to isolated Hbs detected in Hb samples from healthy individuals and from patients with various disorders that produce hemoglobin variants (Table 1). The mass spectrum of the HbA 1b fraction ( Fig. 2A) isolated from a patient with glycogenose type I is characterized by 2 posttranslationally modified ␤-chains, of which the peak with mass 15 938 Da represents the pyruvated ␤-chain built by nonenzymatic condensation of pyruvic acid with the ␤-chain amino terminus (1 ). Additionally, the decarboxylated form of the pyruvated ␤-chain (15 894 Da) is present. Pyruvate adducts correspond well with increased pyruvate concentrations in patients with glycogen storage disease type I.
The mass spectrum of a pre-HbA 1c fraction that elutes slightly before HbA 1c (at 30% solvent B), in a sample from a patient with diabetes, is shown in Fig. 2B . In addition to the normal ␣-chain, the glycated ␣-and ␤-chains are detectable at 15 289 and 16 030 Da, respectively. We conclude that pre-HbA 1c must contain a Hb with at least 1 glycated ␣-chain. On the other hand, the HbA 1c fraction (Fig. 2C) , an important diabetes marker, contains the expected ␣-chain and ␤ glyc -chain, leading to the known ␣ 2 ␤ 2 glyc structure. The analysis of a HbC 1 fraction revealed a mass spectrum very similar to that for a normal ␣-chain and a glycated ␤ C -chain, which differs by only 1 Da from glycated ␤-chain (data not shown). In diabetic patients with HbC, therefore, the minor HbC 1 peak represents a dimer ␣␤ C, glyc and must be included in the quantification of glycated Hbs.
The mass spectrum of the HbF 1 fraction, an Hb that appears with high HbF concentrations, exhibits the acetylated G ␥-and A ␥-chains (shoulder of the peak; Fig. 2D ). Acetylation as a posttranslational modification occurs frequently in human proteins. Native Hb, however, is not N-terminally acetylated (except for ␥-globin) because the N-terminal valine of ␣-, ␤-, and ␦-globins inhibits acetylation (28 ) . Both nearly identical ␥-globin chains are expressed by the G ␥-globin and A ␥-globin genes. In humans at the age of 5 months, A ␥-globin chains become predominant (8 ) . Finally, HbF 1 and HbF (␣ 2 ␥ 2 ) are increased in patients with homozygous HbS on hydroxyurea treatment. This drug increases, by as yet unclear processes, the HbF concentration, which inhibits the polymerization of HbS, thereby reducing vaso-occlusive events (29 ) .
HbA 1d3a (Fig. 2E ) and HbA 1d3b (Fig. 2F) , which eluted at 45% and 48% solvent B, respectively, could not be separated completely. Of the 4 intense peaks detected in the HbA 1d3a fraction, the peak at 15 170 Da corresponds to the carbamylated ␣-chain, and the peak at 15 868 Da is consistent with the normal ␤-chain. We attribute the chains with masses of 15 127 and 15 894 Da to the partly overlapping HbA 1d3b fraction. HbA 1d3a is reported to be significantly higher in uremic than in nonuremic patients (4 ). These observations correspond well with our findings of a carbamylated ␣-chain (adduct of urea to the amino terminus of the ␣-chain); on the other hand, the HbA 1d3b fraction exhibited 3 major chains, the normal ␣-and ␤-chains and a modified ␤-chain at 15 894 Da (Fig. 2F) . The characteristic ␣-and ␤-chains in this fraction probably arise partly from overlapping of the highly intense HbA peak. HbA 1d3 is reported to be increased in female heavy drinkers and in alcoholic individuals, but the increase is not statistically significant (11 ) . The first metabolite of ethanol, acetaldehyde, is known to form adducts with Hbs (10 ). We therefore assume that the peak at mass 15 894 Da could be attributed to the ␤-chain adduct with acetaldehyde (␤ ach ), which corresponds well with the observed mass shift of 26 Da. Occasionally, in patients with diabetes, the glutathionylated ␤-chain at mass 16 173 Da is also detected (data not shown), a finding consistent with other reports (4, 12, 13 ) of increased glutathionylated ␤-chain concentrations that lead to increased HbA 1d3b concentrations. Additionally, a minor peak corresponding to a glycated ␣-chain (15 289 Da) was detected. Assuming a dimeric structure of PolyCAT A-separated compounds, we conclude that this fraction must contain at least 2 different Hbs, namely ␣␤ ach and ␣ glyc ␤. The HbA 1d fraction is reported to increase slowly with hemolysate age (30 ) . Possibly, carbamylation plays a crucial role in Hb aging. Elucidation of the aging process, however, will require further studies.
HbBarts (␥ 4 ) and HbH (␤ 4 ), 2 Hbs consisting of only one type of globin chain, are markers for ␣-thalassemia. These Hbs elute at 18% solvent B when PolyCAT A HPLC is used. Analysis of the isolated fraction of HbBarts revealed only 1 intense peak at 16 010 Da, corresponding to the ␥-chain (data not shown).
We also tried to analyze other fractions containing minor Hbs, such as HbA 1a , HbA 1d1 ϩ 2 , and HbA 1e . Low concentrations and strong overlapping of intense Hbs, however, prevented successful analysis of these components. To identify these minor Hbs, a promising strategy is the analysis of disease samples that exhibit increased minor Hbs as observed in the HbA 1b peak isolated from a patient with glycogenose type 1.
We also used analysis of minor Hbs by MALDI-TOF MS to investigate HbA 2 in HbS carriers. It is well established that HbA 2 is increased in the presence of the ␤-chain variant HbS (5, 19 -21 ) when analyzed by chromatographic methods. Additionally, HbA 2 is reported to inhibit polymerization of deoxy-sickle hemoglobin (HbS) in vitro (31 ) . In this study, we analyzed samples from HbS carriers and compared their HbA 2 values with the values for controls and confirmed ␤-thalassemia carriers. The HbA 2 concentrations of the HbS patients were clearly increased compared with those of the controls (Table 2) and agree with those of Shokrani et al. (5 ) . In 1996, Suh et al. (19 ) undertook a study to investigate the increased HbA 2 concentrations in greater detail. They assumed that coelution of HbS adducts, including glycated HbS with HbA 2 on HPLC, was responsible for the increased HbA 2 value. They were not able, however, to elucidate the supposed coeluting Hb component.
To investigate this proposed HbS adduct, we analyzed isolated HbA 2 fractions of HbS and ␤-thalassemia samples with MALDI-TOF MS. In the HbA 2 fraction of a patient with ␤-thalassemia (without HbS), the expected ␣-and ␦-chains (Fig. 3A) were present. The different signal intensities of the 2 peaks resulted from distinct mass spectrometric signal responses and not from various amounts of the globin chains. In contrast to the spectrum of the ␤-thalassemia sample, we found in all investigated HbS samples additional globin chains at 15 170 and 15 838 Da (Fig. 3B) . The 15 838-Da globin chain could easily be assigned to the variant ␤-chain, ␤ S . The presence of the ␤ S -chain in the HbA 2 fraction is explained by incomplete separation of an intense HbS peak and the HbA 2 peak when analyzed with cation-exchange HPLC. In heterozygous HbS samples, we also detected the peak at 15 838 Da, but we could separate the HbS peak and the ⌯bA 2 peak completely. We therefore conclude that the variant ␤ Schain is participating in coelution of the minor Hb with HbA 2 .
The peak at 15 170 Da must be assigned to a posttranslationally modified ␣-chain. Considering the previously found globin chains in HbA 1d3a , we suspected that the modification is carbamylation of the ␣-chain. Mass spectrometric analysis of the peptides resulting from endoproteinase Glu-C digestion of the HbA 2 fraction confirmed this assumption (data not shown). From these results, we conclude that the increase in HbA 2 in patients with HbS cannot be attributed to the presence of glycated ␤ S , as is commonly accepted, but arises from coelution of the minor Hb ␣ carb ␤ S with HbA 2 .
